Jing Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jing Zhang has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Hong-Yong Cui
Department of Cell Biology and National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi’an, China
28 shared publications - Cai-Feng Xiong
Air Force Medical University, Xi'an, China
14 shared publications - Fei Kang
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi’an, China
14 shared publications - Gang Nan
Air Force Medical University, Xi'an, China
14 shared publications - Hai Zhang
Laboratory Animal Center, The Fourth Military Medical University, Xi’an 710032, China
14 shared publications - Hao Wang
Fourth Military Medical University, China
14 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 12 (2) , e70086
ATM immunohistochemistry as an effective screening method for POLE variants among endometrial carcinomas lacking mismatch repair deficiency and p53 abnormalities
The molecular classification of endometrial carcinomas (ECs) is now integrated into clinical practice. However, identification of polymerase‐ε ( POLE ) variants remains reliant on DNA sequencing, which limits broader implementation. Given the strong prognostic value of pathogenic POLE mutations and the established efficacy of immunohistochemistry (IHC) for detecting mismatch repair (MMR) deficiency and p53 abnormalities, there is a clear need for IHC‐based screening strategies to identify patients likely to carry POLE variants and prioritize them for confirmatory sequencing. In this study, we analyzed 24 cases with POLE pathogenic mutations ( POLE mut ECs), 3 with benign POLE variants, and 32 matched cases with no specific molecular profile (NSMP) from a cohort of 378 ECs. IHC evaluation of the ataxia telangiectasia mutated (ATM) protein revealed that POLE ‐mutated ECs (with pathogenic or benign POLE variants) exhibited significantly higher frequencies of non‐diffuse positive staining patterns, including null, heterogeneous positive, and subclonal loss, compared with NSMP cases. Targeted next‐generation sequencing of all exons across 474 cancer‐related genes in the 27 POLE ‐mutated ECs and 20 NSMP cases with ATM non‐diffuse positive staining patterns confirmed that POLE ‐mutated ECs typically had high tumor mutational burden and were enriched for ATM truncating variants. ATM molecular alterations, including various variant subtypes and multisite mutations, also closely correlated with these staining patterns. Based on these findings, we refined the ATM IHC interpretation framework to integrate staining patterns with sequencing data for improved molecular correlation. Specifically, the null and subclonal loss patterns showed high specificity (96.9%), positive predictive value (94.1%), and accuracy (79.7%) for identifying POLE variants. Notably, the null pattern appeared exclusively in ECs with pathogenic POLE mutations. These results suggest that ATM IHC staining is an effective screening tool for identifying patients who may benefit from confirmatory POLE sequencing among those lacking MMR deficiency or p53 abnormalities.
- 27 March 2026
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 12 (2) , e70086
Open AccessATM immunohistochemistry as an effective screening method for POLE variants among endometrial carcinomas lacking mismatch repair deficiency and p53 abnormalities
The molecular classification of endometrial carcinomas (ECs) is now integrated into clinical practice. However, identification of polymerase‐ε ( POLE ) variants remains reliant on DNA sequencing, which limits broader implementation. Given the strong prognostic value of pathogenic POLE mutations and the established efficacy of immunohistochemistry (IHC) for detecting mismatch repair (MMR) deficiency and p53 abnormalities, there is a clear need for IHC‐based screening strategies to identify patients likely to carry POLE variants and prioritize them for confirmatory sequencing. In this study, we analyzed 24 cases with POLE pathogenic mutations ( POLE mut ECs), 3 with benign POLE variants, and 32 matched cases with no specific molecular profile (NSMP) from a cohort of 378 ECs. IHC evaluation of the ataxia telangiectasia mutated (ATM) protein revealed that POLE ‐mutated ECs (with pathogenic or benign POLE variants) exhibited significantly higher frequencies of non‐diffuse positive staining patterns, including null, heterogeneous positive, and subclonal loss, compared with NSMP cases. Targeted next‐generation sequencing of all exons across 474 cancer‐related genes in the 27 POLE ‐mutated ECs and 20 NSMP cases with ATM non‐diffuse positive staining patterns confirmed that POLE ‐mutated ECs typically had high tumor mutational burden and were enriched for ATM truncating variants. ATM molecular alterations, including various variant subtypes and multisite mutations, also closely correlated with these staining patterns. Based on these findings, we refined the ATM IHC interpretation framework to integrate staining patterns with sequencing data for improved molecular correlation. Specifically, the null and subclonal loss patterns showed high specificity (96.9%), positive predictive value (94.1%), and accuracy (79.7%) for identifying POLE variants. Notably, the null pattern appeared exclusively in ECs with pathogenic POLE mutations. These results suggest that ATM IHC staining is an effective screening tool for identifying patients who may benefit from confirmatory POLE sequencing among those lacking MMR deficiency or p53 abnormalities.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Table S8 The diagnostic accuracy of each biopsy in the combination of PSMA-TB and TRUS-GB
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Table S8 The diagnostic accuracy of each biopsy in the combination of PSMA-TB and TRUS-GB
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Representativeness of Study Participants
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Representativeness of Study Participants
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Distribution of Gleason scores according to the PI-RADS score.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Distribution of Gleason scores according to the PI-RADS score.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Figure S2. The distribution of SUVmax in different GS groups.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Figure S2. The distribution of SUVmax in different GS groups.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Table S6. Adverse events in the two groups subjected to prostate biopsy
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Table S6. Adverse events in the two groups subjected to prostate biopsy
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Table S2. Intraclass correlation coefficient of SUVmax measurement
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Table S2. Intraclass correlation coefficient of SUVmax measurement
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Table S5 The diagnostic performance of PSMA PET in combined and control group
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET–Targeted Prostate Biopsy for Prostate Cancer Diagnosis
Table S5 The diagnostic performance of PSMA PET in combined and control group